Open AccessAnti‐neutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): a new seromarker for inflammatory bowel disease and associated disorders
Author(s) -
STOFFEL M. P.,
CSERNOK E.,
HERZBERG C.,
JOHNSTON T.,
CARROLL S. F.,
GROSS W. L.
Publication year - 1996
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1046/j.1365-2249.1996.d01-654.x
Subject(s) - primary sclerosing cholangitis , medicine , inflammatory bowel disease , anti neutrophil cytoplasmic antibody , immunology , antibody , ulcerative colitis , disease , vasculitis
It was our purpose to determine the immunodiagnostic value of ANCA directed against BPI in diseases known to be associated with ANCA, such as ANCA‐associated vasculitides, inflammatory bowel disease (IBD) and the associated condition primary sclerosing cholangitis. The immunoreactivity of recombinant BPI (rBPI) was established in order to develop an ELISA specific for rBPI. By means of this assay, BPI‐ANCA were assessed in sera of 178 patients with IBD or the associated disorder primary sclerosing cholangitis, 112 patients with ANCA‐associated vasculitides, and in sera of 182 disease and 140 healthy controls. BPI‐ANCA were found to be closely associated with IBD and primary sclerosing cholangitis (34% and 44% of ANCA‐positive sera, respectively). By contrast, BPI‐ANCA positivity was low (<10%) in the double‐negative sera of patients with ANCA‐associated vasculitides and in disease and healthy controls. BPI‐ANCA appear to constitute an important marker for IBD and primary sclerosing cholangitis, but not for the ANCA‐associated vasculitides.